Trial Profile
A Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir plus Sofosbuvir With and Without Ribavirin in Direct Acting Antiviral (DAA) Experienced Patients With HCV Genotype 1 Infection With and Without Cirrhosis - the Quartz-I Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2016
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 17 Apr 2016 Results presented at The International Liver Congress 2016
- 11 Mar 2016 New trial record